Badri Dasu Purchases 35,000 Shares of Talphera (NASDAQ:TLPH) Stock

Talphera, Inc. (NASDAQ:TLPH) insider Badri Dasu bought 35,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $0.81 per share, with a total value of $28,350.00. Following the purchase, the insider directly owned 76,230 shares in the company, valued at $61,746.30. The trade was a 84.89% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Talphera Price Performance

Talphera stock opened at $0.78 on Friday. The stock has a market capitalization of $36.20 million, a P/E ratio of -2.04 and a beta of 0.46. Talphera, Inc. has a 12-month low of $0.38 and a 12-month high of $1.57. The firm’s 50-day moving average is $1.00 and its two-hundred day moving average is $0.99.

Institutional Investors Weigh In On Talphera

A number of institutional investors have recently bought and sold shares of the stock. Group One Trading LLC grew its stake in shares of Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares during the period. Virtu Financial LLC acquired a new stake in shares of Talphera in the third quarter valued at about $29,000. Persistent Asset Partners Ltd purchased a new stake in shares of Talphera during the fourth quarter valued at approximately $42,000. Mariner LLC raised its stake in shares of Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC acquired a new position in shares of Talphera during the third quarter worth $89,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TLPH has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. Wall Street Zen upgraded Talphera to a “hold” rating in a report on Saturday, November 1st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.